Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    JNK3 – Something New for Alzheimer’s?

    There’s been an interesting recent development in the biology of Alzheimer’s disease. c-Jun N-terminal kinase 3 (JNK3, known to those in the field, semi-affectionately, as “Junk-Three”) is expressed mostly in the CNS, and has been implicated as a player in Parkinson’s and neurodegeneration in general. There’s bee… Read More
  • Alzheimer's Disease

    The Coming Battle Over Alzheimer’s Disease

    Solanezumab is a story that won’t go away. Eli Lilly’s antibody therapy for Alzheimer’s is the subject of a lot of arguing among investors: some people (and I’m one of them) think that there is no strong evidence for its efficacy, not yet, and that the amount of time and effort devoted to finding that… Read More
  • Alzheimer's Disease

    Another Prospective Alzheimer’s Trial

    I wrote here about a prospective Alzheimer’s trial that’s starting soon among a population in Colombia, and now comes word of another large effort along the same lines. DIAN, the Dominantly Inherited Alzheimer’s Network, will test several current Alzheimer’s candidates in groups of people around the world with genetic mutati… Read More
  • Alzheimer's Disease

    Lilly’s Solanezumab: Did It Actually Work?

    “Hope Rises For Alzheimer’s Treatment, Scientists Say”. Not this scientist. That’s a composite of headlines, but it captures the unfortunate tone. We’re talking about solanezumab, Eli Lilly’s antibody therapy. The company presented analysis of their trial data yesterday, and put a very optimistic face on things.… Read More
  • Alzheimer's Disease

    Lilly’s Solanezumab: A Miss or a Win?

    Lilly has reported results from its anti-amyloid antibody, solanezumab, and. . .well, it’s mixed. And it’s either quite good news, or quite bad. You make the call. The therapy missed its endpoints (both “cognitive and functional”, according to the company) in two clinical trials, so that’s clearly bad news. Progression… Read More
  • Alzheimer's Disease

    Bapineuzumab Still Does Not Work Against Alzheimer’s

    As expected (by all but the most relentlessly optimistic observers), the anti-Alzheimers antibody bapineuzumab has now failed in its most likely patient population. Results came out last night about from patients who do not carry the ApoE4 mutation, the only group that seemed to offer hope in earlier clinical trials. The therapy missed its endpoint… Read More
  • Alzheimer's Disease

    An Alzheimer’s Update: Amyloid Lives?

    There’s a good state-of-the-field post over at Chemiotics on Alzheimer’s, in the wake of the bapineuzumab news the other day. Of particular interest is the recent finding by deCODE and Genentech researchers that there’s a mutation in the Alzheimer’s precursor protein (APP) that actually seems to be protective against the dis… Read More
  • Alzheimer's Disease

    Bapineuzumab Does Not Work Against Alzheimer’s

    This long, long story may finally be coming to an end. Immune-based therapies against beta-amyloid (and the associated amyloid plaques) have been in development for many years now (an excellent review here), and Elan has been in the thick of it for most of that time. Phase II results for this antibody came out in… Read More
  • Alzheimer's Disease

    Live By The Bricks, Die By The Bricks

    I wanted to highlight a couple of recent examples from the literature to show what happens (all too often) when you start to optimize med-chem compounds. The earlier phases of a project tend to drive on potency and selectivity, and the usual way to get these things is to add more stuff to your structures. Read More
  • Alzheimer's Disease

    Strangely Good Results in Diabetes and Cardiovascular Disease

    I’ve read a couple of medical papers recently that show how tricky it is to draw conclusions on what patients would be best helped by a specific therapy. Many of you will have seen the paper in The Lancet on the use of statins in low-risk patients. This isn’t something you’d necessarily think would do… Read More
...789...